FibroBiologics Inc. has filed a Phase 1/2 Investigational New Drug $(IND)$ application with the U.S. Food and Drug Administration (FDA) to advance clinical development of CYPS317, an investigational allogeneic fibroblast spheroid-based therapy for the treatment of moderate to severe psoriasis. The IND submission seeks regulatory clearance to initiate first-in-human clinical trials and includes comprehensive preclinical pharmacology, safety, and manufacturing data. This filing marks a significant step in the company's efforts to develop innovative therapies for chronic inflammatory diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9618405-en) on December 31, 2025, and is solely responsible for the information contained therein.